Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1975 Jul;32(1):1–4. doi: 10.1038/bjc.1975.126

A preliminary report on the effects of methanol extraction residue of BCG (MER) on cancer patients.

E Robinson, A Bartal, Y Cohen, R Haasz
PMCID: PMC2024786  PMID: 1100088

Abstract

Twenty-seven patients with malignant neoplasia were injected intradermally with the methanol extraction residue (MER) fraction of tubercle bacilli. Two schedules of treatment were used: every other week and once a month; 1-10 courses of MER were administered to the patients. The skin reactivity to 3 recall antigens, as well as to the injected MER itself, was used to monitor the immune response. Improvement of skin reactivity occurred in 9 of 18 patients tested with recall antigens. Five of 6 patients treated every other week improved in their immune capacity whereas only 4 of 12 patients improved on the monthly schedule. Thus, repeated injections given every other week were more effective in increasing the cutaneous reactivity than monthly injections of MER. The side-effects of MER treatment were tolerable.

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin R. W., Pimm M. V. BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells. Br J Cancer. 1973 Jan;27(1):48–54. doi: 10.1038/bjc.1973.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baldwin R. W., Pimm M. V. BCG immunotherapy of rat tumors of defined immunogenicity. Natl Cancer Inst Monogr. 1973 Dec;39:11–19. [PubMed] [Google Scholar]
  3. Bast R. C., Jr, Zbar B., Borsos T., Rapp H. J. BCG and cancer. N Engl J Med. 1974 Jun 27;290(26):1458–1469. doi: 10.1056/NEJM197406272902605. [DOI] [PubMed] [Google Scholar]
  4. Gutterman J. U., Mavligit G., Gottlieb J. A., Burgess M. A., McBride C. E., Einhorn L., Freireich E. J., Hersh E. M. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. N Engl J Med. 1974 Sep 19;291(12):592–597. doi: 10.1056/NEJM197409192911202. [DOI] [PubMed] [Google Scholar]
  5. Mathé G., Amiel J. L., Schwarzenberg L., Schneider M., Cattan A., Schlumberger J. R., Hayat M., De Vassal F. Active immunotherapy for acute lymphoblastic leukaemia. Lancet. 1969 Apr 5;1(7597):697–699. doi: 10.1016/s0140-6736(69)92648-8. [DOI] [PubMed] [Google Scholar]
  6. Morton D., Eilber F. R., Malmgren R. A., Wood W. C. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970 Jul;68(1):158–164. [PubMed] [Google Scholar]
  7. OLD L. J., CLARKE D. A., BENACERRAF B. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature. 1959 Jul 25;184(Suppl 5):291–292. doi: 10.1038/184291a0. [DOI] [PubMed] [Google Scholar]
  8. Piessens W. F., Heimann R., Legros N., Heuson J. C. Effect of Bacillus Calmette-Guérin on mammary tumor formation and cellular immunity in dimethylbenz(a)anthracene-treated rats. Cancer Res. 1971 Aug;31(8):1061–1065. [PubMed] [Google Scholar]
  9. Piessens W. F., Lachapelle F. L., Legros N., Heuson J. C. Facilitation of rat mammary tumour growth by BCG. Nature. 1970 Dec 19;228(5277):1210–1211. doi: 10.1038/2281210a0. [DOI] [PubMed] [Google Scholar]
  10. Sparks F. C., Silverstein M. J., Hunt J. S., Haskell C. M., Pilch Y. H., Morton D. L. Complications of BCG immunotherapy in patients with cancer. N Engl J Med. 1973 Oct 18;289(16):827–830. doi: 10.1056/NEJM197310182891603. [DOI] [PubMed] [Google Scholar]
  11. WEISS D. W., DUBOS R. J. Antituberculous immunity induced in mice by vaccination with killed tubercle bacilli or with a soluble bacillary extract. J Exp Med. 1955 Mar 1;101(3):313–330. doi: 10.1084/jem.101.3.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Weiss D. W., Bonhag R. S., Leslie P. Studies on the heterologous immunogenicity of a methanol-insoluble fraction of attenuated tubercle bacilli (BCG). II. Protection against tumor isografts. J Exp Med. 1966 Dec 1;124(6):1039–1065. doi: 10.1084/jem.124.6.1039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Weiss D. W. Nonspecific stimulation and modulation of the immune response and of states of resistance by the methanol-extraction residue fraction of tubercle bacilli. Natl Cancer Inst Monogr. 1972 Dec;35:157–171. [PubMed] [Google Scholar]
  14. Yron I., Weiss D. W., Robinson E., Cohen D., Adelberg M. G., Mekori T., Haber M. Immunotherapeutic studies in mice with the methanol-extraction residue (mer) fraction of BCG: solid tumors. Natl Cancer Inst Monogr. 1973 Dec;39:33–55. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES